Skip to main content
SpringerLink
Log in

Azimilide

NE 10064, Stedicor®

  • Section 1: Antiarrhythmic Agent
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Karam R, Marcello S, Brooks RR, et al. Azimilide dihydrocholoride, a novel antiarrhythmic agent. Am J Cardiol 1998; 81: 40–6

    Article  Google Scholar 

  2. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993; 22: 810–8

    Article  PubMed  CAS  Google Scholar 

  3. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259–71

    Article  PubMed  CAS  Google Scholar 

  4. Miller KE, Carpenter JF, Brooks RR. Beta-adrenergic effects of the class III antiarrhythmic agent NE-10064 in the isolated perfused guinea pig heart. FASEB J 1993; 7 Pt 1: A108

    Google Scholar 

  5. McIntosh MA, Tanira M, Pacini D, et al. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 1994; 23: 653–7

    Article  PubMed  CAS  Google Scholar 

  6. Miller KE, Decker GE, Brittain D, et al. The class III antiarrhythmic NE-10064 suppresses ouabain-induced arrhythmias in guinea pigs. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 82

    Google Scholar 

  7. Busch AE, Malloy KJ, Varnum MD, et al. A slowly-activating potassium current IKs is the target for class III antiarrhythmic drug NE-10064. Circulation 1993; 88 Suppl. Pt 2: 231

    Google Scholar 

  8. Gintant GA. Paradoxical effect of combined administration of class III agents on the canine ventricular action potential. Circulation 1996; 94 Suppl.: 160

    Google Scholar 

  9. Brooks RR, Butterfield JL. The class III antiarrhythmic NE-10064 increases QTc interval with minor hemodynamic effects in anesthetized dogs. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 79

    Google Scholar 

  10. Brooks RR, Carpenter JF, Maynard AE, et al. Efficacy of a novel class III antiarrhythmic agent NE-10064 against ischemia/ reperfusion arrhythmias in rats. FASEB J 1993; 7 (Pt 1): A97

    Google Scholar 

  11. Drexler AP, Micklas JM, Brooks RR. Effects of intravenously administered NE-10064 on programmed electrical stimulation- induced ventricular arrhythmias in anesthetized infarcted dogs. FASEB J 1993; 7 (Pt 1): A97

    Google Scholar 

  12. Nattel S, Liu L, St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998; 37: 627–35

    Article  PubMed  CAS  Google Scholar 

  13. Lavine SJ, Prcevski P. Comparison of hemodynamic effects of 2 type III antiarrhythmic agents in dogs with chronic ischemic left ventricular dysfunction. J Investig Med 1996; 44: 211

    Google Scholar 

  14. Pritchett E, Page R, Connolly S, et al. Azimilide treatment of atrial fibrillation. Circulation 1998; 98 Suppl.: 633

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azimilide. Drugs in R&D 1, 297–300 (1999). https://doi.org/10.2165/00126839-199901040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901040-00003

Keywords

Search

Navigation